What is the recommended dosing, monitoring, and considerations for using Truvada (emtricitabine + tenofovir disoproxil fumarate) together with Isentress (raltegravir) in an adult with HIV‑1 infection?

Truvada plus Isentress for HIV-1 Treatment

For treatment-naïve adults with HIV-1 infection, Truvada (tenofovir disoproxil fumarate/emtricitabine) 300/200 mg once daily plus Isentress (raltegravir) 400 mg twice daily (or 1200 mg once daily with the newer formulation) is an effective and well-tolerated regimen, though integrase inhibitor-based regimens with dolutegravir or bictegravir are now preferred as first-line options.

Dosing Recommendations

Standard Dosing

• Truvada: One tablet (300 mg TDF/200 mg FTC) once daily, with or without food 1
• Isentress:
  • Traditional formulation: 400 mg twice daily 2
  • Newer formulation: 1200 mg (two 600 mg tablets) once daily 3

The once-daily raltegravir formulation demonstrated non-inferiority to twice-daily dosing, with 89% vs 88% achieving HIV-1 RNA <40 copies/mL at week 48 3. This simplifies the regimen to once-daily Truvada plus once-daily raltegravir.

Renal Dose Adjustments

For Truvada in HIV treatment 1:

• CrCl ≥50 mL/min: No adjustment needed
• CrCl 30-49 mL/min: Dose every 48 hours
• CrCl <30 mL/min: Do not use

Clinical Efficacy

This combination has demonstrated robust efficacy in treatment-naïve patients. In the landmark STARTMRK trial, raltegravir plus tenofovir/emtricitabine showed superior outcomes to efavirenz-based therapy through 156 weeks, with 75.4% achieving viral suppression <50 copies/mL 4. The regimen produced mean CD4 increases of 332 cells/mm³ and maintained durable viral suppression across all demographic subgroups 4.

A head-to-head comparison demonstrated equivalence among raltegravir, ritonavir-boosted atazanavir, and ritonavir-boosted darunavir (all with tenofovir/emtricitabine) for virologic control, though raltegravir showed superior combined efficacy and tolerability 5.

Monitoring Requirements

Before Initiation

• HIV-1 antibody/antigen testing to confirm diagnosis 6
• HIV genotypic resistance testing (do not delay treatment for results) 7
• Serum creatinine and estimated creatinine clearance 1
• Hepatitis B surface antigen 6
• Hepatitis C antibody 6
• Complete blood count, comprehensive metabolic panel
• Fasting lipid panel and glucose
• Pregnancy test if applicable 6
• STI screening (gonorrhea, chlamydia, syphilis) 6

During Treatment

• HIV-1 RNA: At 1 month after initiation, then every 3-4 months until suppressed, then every 6 months 8
• CD4 count: Every 3-6 months initially, can extend to annually once stable and >350 cells/μL
• Renal function: Creatinine clearance at 1 month, then every 3-6 months 1
• Urinalysis: Monitor for proteinuria and glucosuria every 6 months 1
• Bone density: Consider baseline and periodic DEXA scans, especially in patients with risk factors 4
• Lipid panel: Every 6-12 months (raltegravir has favorable lipid profile) 4
• STI screening: Every 3-6 months based on risk 6

Safety and Tolerability

Raltegravir demonstrates excellent tolerability. In the STARTMRK trial, only 5% discontinued due to adverse events compared to 7% with efavirenz 4. Drug-related clinical adverse events occurred in 49% with raltegravir versus 80% with efavirenz 4.

Common adverse effects with this combination include:

• Nausea (7%)
• Headache (3-5%)
• Dizziness (2-3%)
• Insomnia 3, 4

Key advantages of raltegravir over other options 8, 2, 4:

• Fewest drug-drug interactions among antiretrovirals
• Can be taken with or without food
• No significant lipid elevations (unlike efavirenz or protease inhibitors)
• Longest safety record among integrase inhibitors
• Superior tolerability in comparative trials

Important Considerations and Caveats

Resistance Profile

Raltegravir has a lower genetic barrier to resistance than dolutegravir or bictegravir 8, 2. While resistance at virologic failure is rare with good adherence, it occurs more frequently than with second-generation integrase inhibitors 5. If raltegravir resistance develops, switch to dolutegravir 50 mg twice daily plus at least one fully active agent 6.

Hepatitis B Co-infection

Critical: Truvada treats both HIV and hepatitis B 6, 8. If this regimen is discontinued in HBV co-infected patients, severe acute exacerbations of hepatitis B can occur 1. Either continue tenofovir-containing therapy or provide alternative HBV treatment.

Pregnancy Considerations

While this combination can be used in pregnancy, dolutegravir-based regimens are now preferred due to superior efficacy and once-daily dosing 7. If using raltegravir in pregnancy, the 400 mg twice-daily formulation is preferred due to more extensive safety data 8.

Why Not First-Line in 2024-2025?

Current guidelines prioritize 6, 7:

1. Bictegravir/TAF/FTC (single-tablet, once-daily)
2. Dolutegravir/TAF/FTC or Dolutegravir/3TC (higher barrier to resistance, once-daily)

These regimens offer:

• Single-tablet convenience
• Higher genetic barrier to resistance
• Once-daily dosing for all components
• Superior outcomes in head-to-head trials

However, raltegravir plus Truvada remains appropriate when:

• Drug interactions preclude dolutegravir or bictegravir
• Patient preference for established safety profile
• Cost considerations favor generic options
• Concerns about weight gain with newer integrase inhibitors

Drug Interactions

Raltegravir has minimal drug interactions 8, 2. No dose adjustment needed with most medications. However, rifampin increases raltegravir clearance; if treating tuberculosis, use dolutegravir instead or increase raltegravir to 800 mg twice daily 7.

Switching Considerations

For virologically suppressed patients on this regimen, switching to newer single-tablet regimens (bictegravir/TAF/FTC or dolutegravir-based) is reasonable for simplification 6, 8. However, if the current regimen is well-tolerated without toxicity, there is little reason to switch 8.

Do not switch to regimens with lower genetic barriers (like rilpivirine) if there is any history of virologic failure or NRTI resistance mutations 6.